Synopsis
========

SPARC tumor positive and stromal negative expression and curative resection independently predicted favorable OS rates in MF-CCA after surgery.

Introduction
============

Cholangiocarcinoma (CCA) is a relatively rare malignancy of the hepatobiliary system; however, the incidence and mortality of CCA are increasing worldwide.[@b1-ott-8-1899]--[@b3-ott-8-1899] Intrahepatic CCA is the second most common hepatic malignancy, accounting for 10%--15% of all primary liver malignancies,[@b4-ott-8-1899] including mass-forming (MF), periductal-infiltrating, and intraductal papillary types grossly.[@b5-ott-8-1899] The MF type comprised the most common subtype of CCA with high possibility of recurrence in the remnant liver even with curative resection.

Clinically, CCA is still challenging nowadays and usually presents at advanced stage. Curative resection with uninvolved surgical margins is treatment of choice, but recurrence is common.[@b6-ott-8-1899] Although liver transplantation has provided an alternative instead of hepatectomy, frequent recurrence following transplantation limits the application of this alternative.[@b7-ott-8-1899] The biological behavior of the CCA and its early recurrence limit the efficacy of surgery with unsatisfactory clinical outcome.[@b6-ott-8-1899],[@b8-ott-8-1899]--[@b12-ott-8-1899] Furthermore, radiotherapy or chemotherapy does not markedly improve long-term survival.[@b10-ott-8-1899],[@b12-ott-8-1899]

Intrahepatic CCA is a desmoplastic tumor that is similar to pancreatic adenocarcinoma. Utispan et al had reported the gene expression profile of CCA-derived fibroblasts revealing the upregulated SPARC (secreted protein acidic and rich in cysteine) or osteonectin/BM40 gene, compared with fibroblasts from the liver without malignancy.[@b13-ott-8-1899] Seol et al used DNA microarrays to analyze and compare the gene expression between CCA cell lines and normal biliary cells. The SPARC gene is overexpressed by both CCA cell lines and human tissue samples.[@b14-ott-8-1899]

SPARC is a calcium-binding protein interacting with the extracellular matrix. SPARC influences cell migration,[@b15-ott-8-1899] proliferation, angiogenesis, matrix cell adhesion, and tissue remodeling. SPARC is an indicator of activated fibroblasts.[@b16-ott-8-1899] The cell growth inhibition from SPARC is demonstrated by SPARC-knockout mice with faster tumor growing than mice expressing SPARC.[@b17-ott-8-1899],[@b18-ott-8-1899] Its expression is often unseen in pancreatic cancer cells through aberrant DNA methylation, but juxtatumoral fibroblasts often express SPARC.[@b19-ott-8-1899] The phenomenon implicates the SPARC's complicated role in tumorigenesis. Increased SPARC expression has been described in malignancies from different origins, including colon, esophagus,[@b20-ott-8-1899] pancreas,[@b19-ott-8-1899] breast,[@b21-ott-8-1899] lung,[@b22-ott-8-1899] brain, urinary bladder,[@b23-ott-8-1899] kidney,[@b24-ott-8-1899] and melanoma. SPARC may help facilitate metastasis of cancer cells from prostate and breast in vitro,[@b25-ott-8-1899],[@b26-ott-8-1899] explaining SPARC overexpression was associated with poor prognosis.[@b20-ott-8-1899],[@b21-ott-8-1899],[@b23-ott-8-1899],[@b27-ott-8-1899],[@b28-ott-8-1899] Although few researches ever specified the expression of SPARC in cancer cells or stroma, its impact on CCA was still lacking.[@b29-ott-8-1899],[@b30-ott-8-1899]

In this study, we evaluated the prognostic significance of SPARC expression in both CCA cancer cells and its stroma in 78 patients after curative hepatectomy for intrahepatic CCA.

Materials and methods
=====================

Demographic features of 78 patients with MF-CCA
-----------------------------------------------

From the CCA registration of the Department of Surgery of Chang Gung Memorial Hospital, 78 MF-CCA patients undergoing hepatectomy between 1989 and 2006 were selected for the current study based on the availability of adequate amount of tumor cells. Intrahepatic CCA was defined as malignant tumor arising from second order or more distal orders of the intrahepatic ducts. Cancers from all the subjects were further classified into three different macroscopic appearances: MF-CCA, periductal-infiltrating CCA, and intraductal papillary CCA. Curative resection was defined as a resection with negative margin microscopically. Surgical mortality was defined as death of patients within the 1st month after hepatectomy. Laboratory tests were conducted on the day before the surgery. Serum carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay. The lesions were preoperatively assessed by abdominal ultrasonography (US), endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography, computed tomography, magnetic resonance cholangiopancreatography, and hepatic arteriography. The pathologic stage of tumor was defined according to the pathological tumor node metastasis classification proposed by the American Joint Committee on Cancer, 6th edition. Adjuvant chemotherapy was intravenously administered with 5-fluorouracil-based regimens for selected patients. Institutional Review Board of the Chang Gung Memorial Hospital approved this study. All the patients were informed and signed informed consent before taking part in the study.

Immunohistochemical study of SPARC in 78 MF-CCA
-----------------------------------------------

Hematoxylin and eosin-stained slides from each patient were reviewed. Specimens of hepatectomy from all MF-CCA patients had been fixed in formalin and embedded in paraffin. A 4 μm section of each specimen was stained for stratifin. The primary antibody against SPARC (clone 1B2, mouse anti-SPARC monoclonal antibody, ab117561; Abcam, Cambridge, UK) was diluted (1:30) and added to the slides that were then incubated overnight at 4°C. The slides were then washed three times for 5 minutes in Tris-buffered saline with Tween-20 before visualization with the Dako labeled streptavidin-biotin2 (LSAB2) system, peroxidase (Dako A/S, No K0675; Dako Denmark A/S, Glostrup, Denmark). Control slides were incubated with a secondary antibody only. After washing three times in Tris-buffered saline with Tween-20 for 5 minutes each, the slides were mounted. Similar to the previous studies published by Sato et al[@b19-ott-8-1899] immunostaining of SPARC was scored by one of the authors blinded to the outcome (C-NY, S-CH \[pathologist\]). SPARC immunostaining was stratified as negative when the intensity was absent to weak (+) and the extent was less than 10%. Immunolabeling was positive if the intensity was moderate (++) to strong (+++) and the extent was ≥10%. SPARC was categorized as positive or negative for both the carcinoma and the normal juxtatumoral tissue of the liver: tumor negative/stroma negative, tumor positive/stroma negative, tumor negative/stroma positive, and tumor positive/stroma positive.

Follow-up study
---------------

The follow-up evaluation in clinical office included physical examinations and blood chemistry tests regularly. Besides, serum levels of CEA and CA 19-9 were checked and remnant liver was examined by US every 3 months. When a suspected finding was revealed by US or elevated levels of tumor markers, abdominal computed tomography or magnetic resonance cholangiopancreatography was arranged for further survey. Moreover, when patients complained of bone pain, bone scans were arranged to detect metastatic bone lesion. If any of the aforementioned examinations revealed recurrence, the patient was hospitalized for a comprehensive and detailed assessment, including angiographic evaluation or magnetic resonance imaging. The management for recurrence included surgery, systemic chemotherapy, external beam radiotherapy, intraluminal radiotherapy, interventional radiological therapy, and hospice care.

Statistical analysis
--------------------

The overall survival (OS) was evaluated with Kaplan--Meier method. Sixteen clinicopathological variables were considered for initial univariable analysis by the log-rank test. The Cox proportional hazards model was applied for multivariate regression. The statistical software SPSS for Windows (SPSS version 17.0; SPSS Inc., Chicago, IL, USA) was used for the statistical analysis. A value of *P*≤0.05 derived from two-tailed test was considered statistically significant.

Results
=======

SPARC staining of human MF-CCA specimens in relation to demographic features
----------------------------------------------------------------------------

In the stroma, SPARC expression was mostly obviously seen in the cytoplasm of peritumoral fibroblasts. The extracellular matrix and other inflammatory cells (macrophages and lymphocytes) did not demonstrate this phenomenon. Fibroblast SPARC expression was most prominent in cells nearby infiltrating cancer cells and was usually weak, or even absent, in the stroma far from cancer cells. Within total 78 subjects, 12 (15.4%) were classified as tumor negative/stroma negative, 37 (47.4%) as tumor positive/stroma negative, four (5.1%) as tumor negative/stroma positive, and 25 (32.1%) as tumor positive/stroma positive ([Figure 1](#f1-ott-8-1899){ref-type="fig"}). Parameters associated with overall mortality were compared for all the 78 patients according to their SPARC status ([Table 1](#t1-ott-8-1899){ref-type="table"}). SPARC patterns were similar irrespective of sex, age, tumor size, nodal status, margin status, and differentiated status.

Analyses for survival and prognosis for MF-CCA patients with hepatectomy
------------------------------------------------------------------------

Seventy-eight MF-CCA patients (33 men and 45 women) with a median age of 59.5 years (range: 29--83 years) received regular follow-up until death after surgery. No patient was excluded from the survival analysis because no surgical mortality occurred in this study (surgical mortality rate: 0% \[0/78\]). A total of 78 MF-CCA patients who had undergone hepatectomy were enrolled in the survival analysis. The median follow-up was 13.6 months (from 1.4 months to 94.1 months). The OS rates at 1 year, 3 years, and 5 years were 55.1%, 22.9%, and 14.9%, respectively.

Log-rank test identified the following factors as favorable influences on the OS rate of 78 MF-CCA patients who had undergone hepatectomy: absence of symptoms, low preoperative alkaline phosphatase (ALK-P) and CEA level, size of tumor \<5 cm, SPARC expression tumor positive and stromal negative, and negative surgical margin status ([Table 2](#t2-ott-8-1899){ref-type="table"}). However, multivariate Cox proportional hazard analysis demonstrated that SPARC expression tumor positive and stromal negative and curative hepatectomy independently predicted a favorable OS rate for MF-CCA patients after hepatectomy ([Table 3](#t3-ott-8-1899){ref-type="table"}, [Figure 2A and B](#f2-ott-8-1899){ref-type="fig"}).

Discussion
==========

This study focused on the value of SPARC for OS prediction in MF-CCA patients who had undergone hepatectomy. Univariate and multivariate analyses were applied to explore the relationship between OS of 78 MF-CCA patients after hepatectomy and 16 clinicopathological factors with relevance, including the SPARC staining status.

Patients who had been diagnosed with MF-CCA asymptomatically and incidentally had a relative favorable survival, but only demonstrated by univariate survival analysis. Clinically, early detection is still challenging because the patients usually do not present without symptoms due to the fact that the symptoms are vague until the disease is quite advanced. That is the reason why more than half of the MF-CCA patients presented with a tumor size \>5 cm clinically. Therefore, searching for a novel tumor marker, especially focusing on patients with high risk, for the early and vigilant detection of CCA is imperative.

Elevated ALK-P level negatively impacts on long-term OS and disease-free survival in both cirrhotic and non-cirrhotic patients as well as in patients with hepatocellular carcinoma larger than 10 cm in diameter.[@b31-ott-8-1899]--[@b34-ott-8-1899] Similarly, our current study also revealed that elevated ALK-P levels impacted negatively on OS following hepatectomy for MF-CCA, as measured by univariate survival analysis. This fact may implicate the existence of liver disease and bile duct obstruction. Furthermore, high preoperative ALK-P level may be correlated with dismal outcome after hepatectomy for metastatic diseases.[@b35-ott-8-1899]

Diagnostic adjuncts for CCA, for example, serum markers, are useful for clinical practice. CA 19-9 and CEA levels had been reported useful for diagnosing CCA in primary sclerosing cholangitis.[@b36-ott-8-1899] The serum level of CA 19-9 is an indicator of tumor burden, and the researchers suggested that elevated CA 19-9 in patients with CCA might be complicated with unresectable disease.[@b36-ott-8-1899] Okabayashi et al reported that elevated serum tumor markers, which include CEA and CA 19-9, were predictive of an unfavorable outcome.[@b37-ott-8-1899] Our current study also showed that CEA is a prognostic predictor for MF-CCA patients after hepatectomy. However, it presented no statistical significance in multivariate analysis.

Hepatic resection is the standard treatment for CCA.[@b38-ott-8-1899] Similar to the findings demonstrated in our previous report, MF-CCA patients without curative resection were exposed to increased possibility of reducing the long-term OS rate by 2.57 times according to Cox proportional hazard analysis.[@b39-ott-8-1899] This fact emphasizes that curative hepatic resection is essential for long-term OS of MF-CCA patients.

Our study revealed that SPARC expression in peritumoral fibroblasts is a strong indicator of poor prognosis in patients with MF-CCA after curative intent hepatectomy (*P*=0.024), patients whose CCA stroma with positive staining for SPARC had a median survival of 8.25 months compared with 17.16 months for those whose stroma was not noted with expression of SPARC. Although bias is inevitable when it comes to retrospective studies, our study is fortified by the fact that some patients were followed over a relatively long clinical course (94.1 months). The point estimates in the multivariate Cox proportional hazards models suggest that stromal SPARC expression may be a practical biomarker in relation to outcome and an equivalent of common clinical parameters, such as positive surgical margins. Although SPARC status was not associated with any clinicopathological feature, SPARC remained an independent factor for outcome prediction in the multivariate analysis.

In our study, we only enrolled patients with surgically curable MF-CCA. Whether this result can be applied to patients with unresectable disease is unknown. According to our result, SPARC expression might be used as an indicator for risk stratification before surgical resection. Until better target therapies specific to SPARC are available, surgical resection should be for all patients with resectable MF-CCA. Furthermore, a tru-cut biopsy is necessary for the evaluation of stromal versus tumor cell SPARC expression. Although biopsy is technically feasible and can increase diagnostic information,[@b40-ott-8-1899] well-conducted studies are necessary to validate its safety and application.

In addition to aforementioned, our study also suggested that the neighboring stroma may be important for the phenotypic behavior of a malignancy. West et al[@b41-ott-8-1899] reported that the host stromal response varies markedly among malignancies. Compared with the gene expression profiles in solitary fibrous tumors and desmoid-type fibromatosis, they suggested that breast cancer may induce distinct stromal reactions. Koukourakis et al[@b42-ott-8-1899] found a strong association between stromal SPARC expression and prognosis in non-small cell lung cancer patients. Jones et al[@b43-ott-8-1899] demonstrated that in breast cancers, SPARC expression in myoepithelial cells compared with luminal cells conferred a worse prognosis, although only approximately 5% of breast cancers expressed SPARC.

The mechanism by which stromal SPARC expression leads to a worse prognosis needed to be further clarified. We did not find a correlation between intratumoral SPARC expression and stromal SPARC expression. However, we believe that peritumoral fibroblast SPARC expression is an indicator of activated fibroblasts. We presume that activated peritumoral fibroblasts is a prelude to poor prognosis by unknown mechanisms.

Previous reports have also demonstrated that a wound-like reaction of fibroblasts indicated poor outcomes in several cancers.[@b44-ott-8-1899] Interestingly, breast cancers revealed different epigenetic profiles of normal stromal fibroblasts and fibroblasts.[@b45-ott-8-1899] Combined tumor- and host-derived factors are likely to initiate the activated fibroblast reaction to infiltrating carcinoma.

SPARC could be regarded as a potential anticancer target. Linolenic acid has been reported to regulate SPARC expression and secretion potentially.[@b46-ott-8-1899] Tumor xenograft from cell lines harboring re-expressing SPARC restored sensitivity to fluorouracil and irinotecan and to radiation.[@b47-ott-8-1899] Abraxane (Abraxis Oncology, Los Angeles, CA, USA) is an albumin-bound 130 nm particle form of paclitaxel, which may be dependent on SPARC expression for its uptake into cells.[@b48-ott-8-1899]--[@b51-ott-8-1899] The prognostic impact of stromal behavior observed in our study implicated that there might be a necessity for searching therapeutic efforts that target not only tumor cells but also the juxtatumoral stroma cells that construct the surrounding microenvironment. As cancer cells undergo clonal evolution independently of stromal cells, the therapeutic targets of stromal cells will be different from those of cancer cells. Just as the success of compounds that target the tumor microenvironment such as bevacizumab and sunitinib,[@b52-ott-8-1899]--[@b54-ott-8-1899] it is reasonable that agents, which target on the activated fibroblast component of the tumor microenvironment, may provide therapeutic effects.

However, many limitations should not be overlooked in this study. First, this is a retrospective study and SPARC expression is an arbitrary classification in these selected patients in this study. To verify the cutoff value of SPARC scoring in MF-CCA patients who had undergone curative hepatic resection, a prospective, randomized study is necessary. Second, to prevent from potential biases of immunohistochemistry quantification, standardized and reliable procedures are necessary to determine SPARC protein function and production.

Third, cancer stromal cells from nearly half of the subjects in our study had tested results of weak or absent SPARC expression, and even with 78 patients of CCA, our study was only moderately powered to distinguish survival status. Finally, it is unclear whether the poorer prognosis among patients with SPARC expressed in the CCA stroma is due to direct effect of SPARC expression or just reflection of an association between the expression of this protein and other aspects of CCA biology.

Conclusion
==========

In summary, stromal SPARC expression is a marker of poor prognosis, independent of common clinical parameters, including surgical margin status. The mechanisms that confer this malignant phenotype warrant further research.
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![Patterns of immunohistochemical expression of SPARC in MF-CCA.\
**Notes:** (**A**) Cancer SPARC expression negative, stromal expression negative; (**B**) cancer SPARC expression positive, stromal expression negative; (**C**) cancer SPARC expression negative, stromal expression positive; and (**D**) cancer SPARC expression positive, stromal expression positive (×400).\
**Abbreviations:** SPARC, secreted protein acidic and rich in cysteine; MF-CCA, mass-forming cholangiocarcinoma.](ott-8-1899Fig1){#f1-ott-8-1899}

![Comparison of OS rate of 78 MF-PCC patients who had undergone hepatectomy in relation to (**A**) resection margin and (**B**) SPARC staining result.\
**Abbreviations:** OS, overall survival; MF-PCC, mass-forming peripheral cholangiocarcinoma; SPARC, secreted protein acidic and rich in cysteine.](ott-8-1899Fig2){#f2-ott-8-1899}

###### 

Clinicopathological features compared between MF-CCA patients with SPARC tumor positive and stromal negative expression and other patients

                              SPARC tumor positive and stromal negative expression (n=37)   Others (n=41)   *P*
  --------------------------- ------------------------------------------------------------- --------------- -------
  Age (years)                 59.98±11.33                                                   59.54±12.68     0.872
  Sex                                                                                                       
   Male                       18 (54.5%)                                                    15 (45.5%)      0.282
   Female                     19 (42.2%)                                                    26 (57.8%)      
  Symptoms                                                                                                  
   Negative                   8 (66.7%)                                                     4 (33.3%)       0.147
   Positive                   29 (43.9%)                                                    37 (56.1%)      
  AST (IU/L)                                                                                                
   ≦34                        20 (51.3%)                                                    19 (48.7%)      0.565
   \>34                       17 (44.7%)                                                    21 (55.3%)      
  ALT (U/L)                                                                                                 
   ≦36                        19 (47.5%)                                                    21 (52.5%)      0.540
   \>36                       17 (54.8%)                                                    14 (45.2%)      
  ALP (U/L)                                                                                                 
    ≦94                       12 (52.2%)                                                    11 (47.8%)      0.525
   \>94                       23 (44.2%)                                                    29 (55.8%)      
  Bilirubin (total) (mg/dL)                                                                                 
    ≦1.3                      33 (51.6%)                                                    31 (48.4%)      0.119
   \>1.3                      4 (28.6%)                                                     10 (71.4%)      
  Albumin (g/dL)                                                                                            
    ≦3.5                      9 (40.9%)                                                     13 (59.1%)      0.528
   \>3.5                      24 (49.0%)                                                    25 (51.0%)      
  Serum CEA (ng/mL)                                                                                         
    ≦5                        9 (36.0%)                                                     16 (64.0%)      0.160
   \>5                        17 (54.8%)                                                    14 (45.2%)      
  Stage                                                                                                     
   I                          14 (37.8%)                                                    11 (26.8%)      0.405
   II                         1 (2.7%)                                                      5 (12.2%)       
   III                        19 (51.4%)                                                    21 (51.2%)      
   IV                         3 (8.1%)                                                      4 (9.8%)        
  Size (cm)                                                                                                 
    ≦5                        14 (43.8%)                                                    18 (56.3%)      0.404
   \>5                        23 (53.5%)                                                    20 (46.5%)      
  Lymph node                                                                                                
   Negative                   22 (46.8%)                                                    25 (53.2%)      0.901
   Positive                   14 (48.3%)                                                    15 (51.7%)      
  Differentiated                                                                                            
   Well                       0 (00.0%)                                                     2 (100.0%)      0.256
   Moderate                   19 (46.3%)                                                    22 (53.7%)      
   Poorly                     16 (48.5%)                                                    17 (51.5%)      
   Others                     2 (100.0%)                                                    0 (00.0%)       
  Margin                                                                                                    
   Negative                   27 (50.0%)                                                    27 (50.0%)      0.496
   Positive                   10 (41.7%)                                                    14 (58.3%)      
  Post-op chemotherapy                                                                                      
   Without                    12 (36.4%)                                                    21 (63.6%)      0.094
   With                       25 (55.6%)                                                    20 (44.4%)      
  Post-op radiotherapy                                                                                      
   Without                    34 (50.0%)                                                    34 (50.0%)      0.317
   With                       3 (30.0%)                                                     7 (70.0%)       

**Abbreviations:** MF-CCA, mass-forming cholangiocarcinoma; SPARC, secreted protein acidic and rich in cysteine; AST, aspartate aminotransferase; IU, international unit; ALT, alanine aminotransferase; ALP, alkaline phosphatase; CEA, carcinoembryonic antigen; op, operation.

###### 

Univariate analysis of factors influencing the overall survival of 78 MF-CCA patients

  Factors                                       Survival time (months)   *P*                          
  --------------------------------------------- ------------------------ -------------- ------ ------ ---------
  Sex                                                                                                 
   Male (n=33)                                  14.70                    7.89--21.50    21.2   18.2   0.719
   Female (n=45)                                10.82                    5.85--15.79    24.4   15.0   
  Age                                                                                                 
   ≦60 (n=38)                                   12.89                    4.45--21.33    26.3   21.1   0.505
   \>60 (n=40)                                  12.99                    7.23--18.74    20.0   12.0   
  Symptoms                                                                                            
   Negative (n=12)                              37.71                    4.78--70.63    58.3   41.7   0.006
   Positive (n=66)                              10.45                    5.84--15.07    16.7   11.9   
  AST (IU/L)                                                                                          
   ≦34 (n=39)                                   13.32                    9.53--17.10    30.8   22.8   0.197
   \>34 (n=38)                                  10.72                    2.28--19.16    15.8   10.5   
  ALT (IU/L)                                                                                          
   ≦36 (n=40)                                   12.99                    6.41--19.56    25.0   19.7   0.625
   \>36 (n=31)                                  14.70                    7.81--21.58    19.4   9.7    
  ALP (IU/L)                                                                                          
   ≦94 (n=23)                                   23.90                    11.65--36.15   39.1   29.8   0.009
   \>94 (n=52)                                  9.11                     4.92--13.29    15.4   5.0    
  Bil (total) (mg/dL)                                                                                 
   ≦1.3 (n=64)                                  12.99                    6.41--19.56    25.0   16.9   0.581
   \>1.3 (n=14)                                 10.72                    0.00--22.23    14.3   14.3   
  Albumin (g/dL)                                                                                      
   ≦3.5 (n=22)                                  4.70                     3.11--6.29     18.2   13.6   0.063
   \>3.5 (n=49)                                 19.04                    13.31--24.76   24.5   15.9   
  Serum CEA (ng/dL)                                                                                   
   ≦5 (n=25)                                    18.51                    2.09--34.93    40.0   27.0   0.043
   \>5 (n=31)                                   10.29                    4.05--16.53    6.5    6.5    
  Margin                                                                                              
   Negative (n=54)                              19.43                    14.97--23.89   33.3   23.8   \<0.001
   Positive (n=24)                              4.41                     2.43--6.38     0.0    0.0    
  Size                                                                                                
   ≦5 cm (n=32)                                 19.99                    13.75--26.23   37.5   30.7   0.006
   \>5 cm (n=43)                                9.11                     1.97--16.25    14.0   7.0    
  Lymph node                                                                                          
   Negative (n=47)                              19.89                    16.71--23.07   29.8   18.7   0.063
   Positive (n=29)                              10.45                    0.00--22.71    13.8   13.8   
  Histology                                                                                           
   Well (n=2)                                   2.73                     NA             0.0    0.0    0.207
   Moderate (n=41)                              13.84                    7.45--20.23    22.0   17.1   
   Poor (n=33)                                  12.99                    5.25--20.72    27.3   17.3   
   Others (n=2)                                 4.37                     NA             0.0    0.0    
  SPARC expression                                                                                    
   Tumor positive and stromal negative (n=37)   17.16                    9.21--25.12    29.7   27.0   0.022
   Others (n=41)                                8.25                     3.88--12.62    17.1   6.5    
  Post-op chemotherapy                                                                                
   Without (n=33)                               5.65                     2.47--8.84     30.3   23.9   0.937
   With (n=45)                                  14.70                    9.64--19.75    17.8   11.1   
  Post-op radiotherapy                                                                                
   Without (n=68)                               13.32                    8.27--18.36    26.5   18.9   0.071
   With (n=10)                                  6.97                     5.29--8.65     0.0    0.0    

**Abbreviations:** MF-CCA, mass-forming cholangiocarcinoma; AST, aspartate aminotransferase; IU, international unit; ALT, alanine aminotransferase; ALP, alkaline phosphatase; Bil, bilirubin; CEA, carcinoembryonic antigen; SPARC, secreted protein acidic and rich in cysteine; op, operation.

###### 

Cox proportional hazards analysis

  Factors                                                               Relative risk (95% CI)   *P*
  --------------------------------------------------------------------- ------------------------ -------
  Symptoms (positive/negative)                                          1.973 (0.811--4.800)     0.134
  ALP (≦94 g/dL/\>94 g/dL)                                              1.136 (0.583--2.213)     0.707
  Serum CEA (ng/dL)                                                     1.784 (0.912--3.491)     0.091
  Tumor size (\>5 cm/≦5 cm)                                             1.641 (0.937--2.876)     0.083
  Margin (positive/negative)                                            2.574 (1.336--4.959)     0.005
  SPARC expression: tumor positive and stromal negative versus others   0.477 (0.251--0.906)     0.024

**Abbreviations:** ALP, alkaline phosphatase; CEA, carcinoembryonic antigen; SPARC, secreted protein acidic and rich in cysteine.
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